Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.Ye Guo, Jin Li, Zhixiang Zhuang et al.|Journal of Clinical Oncology|2023Cited by 11
Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors.Jifang Gong, Lin Shen, Lei Chen et al.|Journal of Clinical Oncology|2023Cited by 6
SO-17 A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancerF. Wang, Renjie Xu, Junlan Xiao et al.|Annals of Oncology|2022Cited by 5
Abstract CT542: Preliminary safety and efficacy results of KN046 in combination with KN026 in patients with locally advanced unresectable or metastatic HER2-positive solid cancerJifang Gong, Lin Shen, Lei Chen et al.|Cancer Research|2022Cited by 3